2,4-diaminoquinazoline derivatives and medical uses thereof

US11597704B2 · kind B2 · utility

Assignee

• Janssen Sciences Ireland Unlimited Company · IE

Inventors

• David Craig MC GOWAN · Brussels, BE
• Werner Constant Johan Embrechts · Beerse, BE
• Jérôme Emile Georges Guillemont · Andé, FR
• Ludwig Paul Cooymans · Beerse, BE
• Tim Hugo Maria Jonckers · Heist-op-den-Berg, BE
• Pierre Jean-Marie Bernard Raboisson · Sligo, IE

Key dates

• Filing date: Feb 28, 2019
• Grant date: Mar 7, 2023
• Expiry date: Feb 28, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P37/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This application relates to quinazoline derivatives of formula (I), pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds of formula (I) in the treatment or prevention of a viral infection, of a virus-induced disease, of cancer or of an allergy. In formula (I), R1 is a C3-8alkyl, optionally substituted by one or more substituents independently selected from fluorine, hydroxyl, amino, nitrile, ester, amide, C1-3 alkyl, or C1-3 alkoxy, the carbon of R1 bonded to the amine in the 4-position of the quinazoline is in (R)-configuration, R2 is hydrogen, deuterium, fluorine, chlorine, methyl, methoxy, cyclopropyl, trifluoromethyl, or carboxylic amide, wherein each of methyl, methoxy and cyclopropyl is optionally substituted by one or more substituents independently selected from fluorine and nitrile, R3 is hydrogen or deuterium, R4 is hydrogen, deuterium, fluorine, methyl, carboxylic ester, carboxylic amide, nitrile, cyclopropyl, C4-7 heterocycle, or 5-membered heteroaryl group, wherein each of methyl, cyclopropyl, C4-7 heterocycle and 5-membered heteroaryl group is optionally substituted by one or more substituents independently selected from fl…